172 related articles for article (PubMed ID: 25255841)
1. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions.
Rangel EB
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1585-605. PubMed ID: 25255841
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
[TBL] [Abstract][Full Text] [Related]
3. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.
Rangel EB
Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1531-48. PubMed ID: 22978385
[TBL] [Abstract][Full Text] [Related]
4. Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences.
Shrestha BM
Exp Clin Transplant; 2017 Feb; 15(1):1-9. PubMed ID: 27938316
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive update of the metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.
Vidigal AC; de Lucena DD; Beyerstedt S; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2023; 19(7):405-427. PubMed ID: 37542452
[TBL] [Abstract][Full Text] [Related]
6. Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer?
Egidi FM
Drugs; 2005; 65(2):153-66. PubMed ID: 15631539
[TBL] [Abstract][Full Text] [Related]
7. Preliminary experience with FK 506 in pancreas transplant recipients.
Stratta RJ; Taylor RJ; Castaldo P; Sindhi R; Sudan D; Frisbie K; Cushing K
Transplant Proc; 1995 Dec; 27(6):3024. PubMed ID: 8539823
[No Abstract] [Full Text] [Related]
8. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation.
Barone GW; Ketel BL; Abul-Ezz SR; Lightfoot ML
JOP; 2002 Mar; 3(2):49-53. PubMed ID: 11884766
[TBL] [Abstract][Full Text] [Related]
9. Minimization protocols in pancreas transplantation.
Cantarovich D; Vistoli F
Transpl Int; 2009 Jan; 22(1):61-8. PubMed ID: 18713147
[TBL] [Abstract][Full Text] [Related]
10. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
[TBL] [Abstract][Full Text] [Related]
11. Post-transplant diabetes mellitus. The role of immunosuppression.
Jindal RM; Sidner RA; Milgrom ML
Drug Saf; 1997 Apr; 16(4):242-57. PubMed ID: 9113492
[TBL] [Abstract][Full Text] [Related]
12. Pancreas transplantation for treatment of diabetes mellitus.
Sutherland DE; Gruessner RW; Gruessner AC
World J Surg; 2001 Apr; 25(4):487-96. PubMed ID: 11344403
[TBL] [Abstract][Full Text] [Related]
13. Update of tacrolimus in pancreas transplantation.
Wijnen RM; Ericzon BG
Diabet Med; 1997 Nov; 14(11):911-8. PubMed ID: 9400914
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression and Post-transplant Hyperglycemia.
Montero N; Pascual J
Curr Diabetes Rev; 2015; 11(3):144-54. PubMed ID: 25824238
[TBL] [Abstract][Full Text] [Related]
15. [Calcineurin inhibitors and mechanisms that are responsible for the appearance of post-transplant diabetes mellitus].
Ippoliti GB; Viganò M
G Ital Nefrol; 2003; 20 Suppl 25():S11-4. PubMed ID: 14523907
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus for the prevention and treatment of rejection of solid organ transplants.
Scalea JR; Levi ST; Ally W; Brayman KL
Expert Rev Clin Immunol; 2016; 12(3):333-42. PubMed ID: 26588770
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use.
Li CJ; Li L
Drug Des Devel Ther; 2015; 9():473-85. PubMed ID: 25609922
[TBL] [Abstract][Full Text] [Related]
19. [Controversies about the use of calcineurin inhibitors in pediatric patients].
Dello Strologo L
G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus based immunosuppression.
First MR
J Nephrol; 2004; 17 Suppl 8():S25-31. PubMed ID: 15599882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
